VHCP Management, LLC - Q3 2013 holdings

$181 Million is the total value of VHCP Management, LLC's 18 reported holdings in Q3 2013. The portfolio turnover from Q2 2013 to Q3 2013 was 0.0% .

 Value Shares↓ Weighting
DYAX  Dyax Corp$28,514,000
+98.3%
4,156,5080.0%15.75%
+47.4%
IRWD  Ironwood Pharmaceuticals Inc$21,312,000
+19.2%
1,800,0000.0%11.77%
-11.3%
KERX  Keryx Biopharmaceuticals Inc$20,672,000
+35.1%
2,048,7730.0%11.42%
+0.4%
ANAC  Anacor Pharmaceuticals Inc$17,107,000
+90.0%
1,610,8560.0%9.45%
+41.3%
GWPH  GW Pharmaceuticals$14,527,000
+96.8%
837,8000.0%8.02%
+46.4%
TSRO  TESARO Inc$10,116,000
+18.3%
261,1300.0%5.59%
-12.0%
CHTP  Chelsea Therapeutics International Ltd$7,525,000
+30.0%
2,516,8700.0%4.16%
-3.3%
THLD  Threshold Pharmaceuticals Inc$3,181,000
-11.6%
684,0000.0%1.76%
-34.2%
ALXA  Alexza Pharmaceuticals Inc$2,048,000
+18.0%
399,9990.0%1.13%
-12.3%
GTXI  GTx Inc$1,013,000
-69.3%
500,0000.0%0.56%
-77.2%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2013-11-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
DBV Technologies14Q4 201633.5%
BioCryst Pharmaceuticals Inc13Q4 201611.9%
Ocera Therapeutics13Q4 20164.9%
Anacor Pharmaceuticals Inc12Q1 201635.6%
Heron Therapeutics Inc12Q4 201620.5%
Flamel Technologies S.A.12Q4 20166.1%
GW Pharmaceuticals11Q4 201519.9%
Lipocine Inc11Q4 20167.5%
Stemline Therapeutics Inc11Q4 20161.7%
Zafgen Inc10Q3 20165.7%

View VHCP Management, LLC's complete holdings history.

Latest filings
TypeFiled
42018-02-28
13F-HR2017-02-13
13F-HR2016-11-14
13F-HR2016-08-12
13F-HR2016-05-13
13F-HR2016-02-12
13F-HR2015-11-13
13F-HR2015-08-13
32015-06-17
13F-HR2015-05-14

View VHCP Management, LLC's complete filings history.

Compare quarters

Export VHCP Management, LLC's holdings